Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase III Study on Bortezomib and Low-Dose Dexamethasone With or Without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma

Next Previous
Search
Trial Profile

Randomized Phase III Study on Bortezomib and Low-Dose Dexamethasone With or Without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Cyclophosphamide
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen-Cilag

    • Most Recent Events

    • 01 Nov 2017 Status changed to discontinued.
    • 01 Nov 2017 Primary endpoint (Time to Progression of Disease) has not been met as per the results published in the Annals of Hematology
    • 01 Nov 2017 Due to a lack of recruitment, the planned sample size of 270 patients was not reached and enrollment was stopped prematurely as a result of a joint decision of the sponsor and coordinating investigator; the study was therefore underpowered with regard to the primary aim of the study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top